- Home
- CAPN vs BEAT Comparison
CAPN vs BEAT Comparison
Compare CAPN & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPN
- BEAT
- Stock Information
- Founded
- CAPN 2024
- BEAT 2015
- Country
- CAPN United States
- BEAT United States
- Employees
- CAPN N/A
- BEAT N/A
- Industry
- CAPN
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- CAPN
- BEAT Technology
- Exchange
- CAPN NYSE
- BEAT Nasdaq
- Market Cap
- CAPN 78.7M
- BEAT 74.1M
- IPO Year
- CAPN 2024
- BEAT 2021
- Fundamental
- Price
- CAPN $10.06
- BEAT $2.14
- Analyst Decision
- CAPN
- BEAT Buy
- Analyst Count
- CAPN 0
- BEAT 1
- Target Price
- CAPN N/A
- BEAT $8.00
- AVG Volume (30 Days)
- CAPN 4.7K
- BEAT 117.1K
- Earning Date
- CAPN 01-01-0001
- BEAT 11-07-2024
- Dividend Yield
- CAPN N/A
- BEAT N/A
- EPS Growth
- CAPN N/A
- BEAT N/A
- EPS
- CAPN N/A
- BEAT N/A
- Revenue
- CAPN N/A
- BEAT N/A
- Revenue This Year
- CAPN N/A
- BEAT N/A
- Revenue Next Year
- CAPN N/A
- BEAT N/A
- P/E Ratio
- CAPN N/A
- BEAT N/A
- Revenue Growth
- CAPN N/A
- BEAT N/A
- 52 Week Low
- CAPN $10.12
- BEAT $1.35
- 52 Week High
- CAPN $10.25
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- CAPN N/A
- BEAT 39.59
- Support Level
- CAPN N/A
- BEAT $2.00
- Resistance Level
- CAPN N/A
- BEAT $2.30
- Average True Range (ATR)
- CAPN 0.00
- BEAT 0.16
- MACD
- CAPN 0.00
- BEAT -0.00
- Stochastic Oscillator
- CAPN 0.00
- BEAT 35.00
About CAPN CAYSON ACQUISITION CORP
Cayson Acquisition Corp is a blank check company.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.